Fibroblast growth factor receptor 3 (FGFR3) expression in malignant lymphomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 4, 2008, Pages 322-325

  Larson, Andrew ^a   Cook, James R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

FGFR3; Fibroblast growth factor receptor 3; Lymphoma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PARAFFIN;

ARTICLE; B CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; CYTOPLASM; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LYMPHOMA; TISSUE MICROARRAY; TISSUE SECTION; BIOSYNTHESIS; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; GENETICS; LYMPHOMA; METABOLISM; PATHOLOGY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA; MULTIPLE MYELOMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; TISSUE ARRAY ANALYSIS;

EID: 48949096007     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31815ace54     Document Type: Article

References (30)

1. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;2:reviews3005.1-3005.12.
2. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer. 2000;7:165-197.
3. L'Hote CG, Knowles MA. Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp Cell Res. 2005;304: 417-431.
4. Passos-Bueno MR, Wilcox WR, Jabs EW, et al. Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat. 1999;14: 115-125.
5. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999;23:18-20.
6. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol. 2004;28:464-470.
7. Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260-264.
8. Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92: 3025-3034.
9. Richelda R, Ronchetti D, Baldini L, et al. A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood. 1997;90:4062-4070.
10. Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005;23: 6333-6338.
11. Keats JJ, Reiman T, Belch AR, et al. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma. 2006;47:2289-2300.
12. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005;24:8259-8267.
13. Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105:2941-2948.
14. Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood. 2006;107:4039-4046.
15. Xin X, Abrams TJ, Hollenbach PW, et al. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice. Clin Cancer Res. 2006;12:4908-4915.
16. Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194:96-104.
17. Khnykin D, Troen G, Berner JM, et al. The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma. J Pathol. 2006;208:431-438.
18. Cook JR, Hartke M, Pettay J, et al. Fluorescence in situ hybridization analysis of immunoglobulin heavy chain translocations in plasma cell myeloma using intact paraffin sections and simultaneous CD138 immunofluorescence. J Mol Diagn. 2006;8: 459-465.
19. Finelli P, Fabris S, Zagano S, et al. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Blood. 1999;94:724-732.
20. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520-1529.
21. Intini D, Baldini L, Fabris S, et al. Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). Br J Haematol. 2001;114:362-364.
22. Onwuazor ON, Wen XY, Wang DY, et al. Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients. Blood. 2003;102: 772-773.
23. Soverini S, Terragna C, Testoni N, et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica. 2002;87: 1036-1040.
24. Chesi M, Bergsagel PL, Kuehl WM. The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression. Curr Opin Hematol. 2002;9:288-293.
25. Li Z, Zhu YX, Plowright EE, et al. The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood. 2001;97:2413-2419.
26. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99: 2185-2191.
27. Chang H, Stewart AK, Qi XY, et al. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood. 2005;106:353-355.
28. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64: 1546-1558.
29. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood. 2005;106: 2837-2840.
30. Tomslinson D, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213:91-98.